A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial
Metastatic Well Differentiated Neuroendocrine Neoplasm|Neuroendocrine Tumors
DRUG: Cabozantinib|DRUG: Lanreotide
Objective Response Rate (ORR), according to RECIST, v1.1 defined as complete response or partial response after treatment administration, 42 months|Primary Safety Endpoint, Adverse Events (AE) grade 3-5 according to NCI-CTCAE v5.0 grade, 42 months
Progression-free survival (PFS), defined as the time from first day of treatment administration until progression disease according to RECIST v 1.1 or death for every cause, whichever occurred first., 42 months|Safety Endpoint, Adverse Event (AE) all grade according to NCI-CTCAE v5.0 grade, 42 months|Clinical effectiveness endpoint, Overall Survival (OS) defined as the time from first treatment administration until death whichever cause, 42 months|Exploratory objectives analysis, the investigation of immunohistochemical tissue expression level of Mesenchymal Epithelial Transition (MET), AXL, vascular endothelial growth factor (VEGFR2) proteins., 42 months
Phase II, multicenter, open-label, non-comparative, non-randomized study with three-stage design